Healthcare / Medical Care FacilitiesNasdaqCM
$0.63
+0.01 (+0.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $27.0M · quality 44.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$62M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-126.7%
↓Gross Margin
30.7%
↓Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+27.9%
FCF CAGR
—
FCF margin
8.4%
FCF / Net income
-0.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $322.2M · net income $-182.4M · FCF $27.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $322.2M | $322.2M | $616.6M | $624.3M | $440.5M | $318.7M | $94.1M |
| Net Income | $-182.4M | $-182.4M | $20.0M | $6.9M | $34.6M | $23.7M | $-14.8M |
| EBITDA | $-73.5M | $-73.5M | $44.6M | $31.5M | $32.4M | $17.7M | $-9.3M |
| EPS | — | — | 0.18 | 0.06 | 0.34 | 0.25 | -0.25 |
| Gross Margin | 30.7% | 30.7% | 34.6% | 31.3% | 35.1% | — | — |
| Operating Margin | -27.7% | -27.7% | 4.7% | 2.4% | 5.0% | 4.8% | -15.7% |
| Net Margin | -56.6% | -56.6% | 3.2% | 1.1% | 7.9% | 7.4% | -15.7% |
| Balance Sheet | |||||||
| Debt/Equity | 0.20 | 0.20 | 0.18 | 0.15 | 0.07 | — | 0.00 |
| Current Ratio | 1.79 | 1.79 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $27.0M | $27.0M | $64.5M | $-74.3M | $23.4M | $-6.8M | $-15.0M |
| Returns | |||||||
| ROE | -126.7% | -126.7% | 6.2% | 2.3% | 12.7% | 10.8% | -26.9% |
| Valuation | |||||||
| P/E | — | — | 24.11 | 82.17 | 21.24 | — | — |
| EV/EBITDA | — | — | 9.94 | 16.13 | 18.71 | — | — |
| P/B | 0.43 | 0.43 | 1.48 | 1.73 | 2.72 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -47.7% | -47.7% | -1.2% | 41.7% | — | 238.7% | — |
| EPS Growth | — | — | 200.0% | -82.4% | — | 200.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.18 → n/d
Residual
-57.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.